(CercleFinance.com) – Noxxon Pharma announces the extension of its agreement with Atlas Special Opportunities (ASO), allowing a capital increase which further strengthens the financial visibility of the biotech company until December 2022.
The extension of the agreement involves the additional provision of up to 17 million euros in equity-related securities and the issuance of 2,419 convertible bonds for a total nominal value of nearly 2.42 million euros. ‘euros.
This gives it guaranteed funding security for the launch of the phase 2/3 study on NOX-A12 in glioblastoma and the phase 2 study in pancreatic cancer, both of which are expected to start in the third quarter of 2022. .